SlideShare une entreprise Scribd logo
1  sur  7
Télécharger pour lire hors ligne
Mavrilimumab Market Analysis and Forecast to 2023
By
GlobalData
Browse More Reports On Life Sciences @
http://www.rnrmarketresearch.com/reports/life-sciences .
© RnRMarketResearch.com ; sales@rnrmarketresearch.com ;
+1 888 391 5441
Single User License: US $3495
Published: Dec 2014
Mavrilimumab Market Analysis and Forecast to 2023
Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and
deformity of the joints. It affects over seven million individuals in the 10MM covered in this
report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the
prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs
have been effective in treating the signs and symptoms of RA and inhibiting progression to
erosive bone disease. However, the landscape is quickly changing with the introduction of
biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which
will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely
effective therapies for RA, the market is extremely competitive for new entrants and will
undergo further pressure as biosimilars are approved and launch.
Complete report available @ http://www.rnrmarketresearch.com/mavrilimumab-
rheumatoid-arthritis-forecast-and-market-analysis-to-2023-market-report.html .
© RnRMarketResearch.com ; sales@rnrmarketresearch.com ;
+1 888 391 5441
© RnRMarketResearch.com ; sales@rnrmarketresearch.com ;
+1 888 391 5441
Mavrilimumab, also known as CAM3001, is in Phase IIb of development for RA by
MedImmune, a subsidiary of AstraZeneca. It is a human mAb targeted against the alpha
subunit of the GM-CSF receptor. GM-CSF levels are elevated in the serum, synovial fluid, and
synoviocytes of patients with RA. Inhibition of GM-CSF activity is proposed to reduce the
activation, differentiation, and recruitment of macrophages and neutrophils in the damaged
and inflamed joints of RA patients.
Scope
• Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Mavrilimumab including product description, safety and efficacy
profiles as well as a SWOT analysis.
• Sales forecast for Mavrilimumab for the top 6 countries from 2013 to 2023.
• Sales information covered for the US, France, Germany, Italy, Spain and the UK.
Purchase a Copy of this Report @
http://www.rnrmarketresearch.com/contacts/purchase?rname=312807 .
Mavrilimumab Market Analysis and Forecast to 2023
© RnRMarketResearch.com ; sales@rnrmarketresearch.com ;
+1 888 391 5441
Reasons to buy
• Understand and capitalize by identifying products that are most likely to ensure a robust
return.
• Stay ahead of the competition by understanding the changing competitive landscape for
Rheumatoid Arthritis.
• Effectively plan your M&A and partnership strategies by identifying drugs with the most
promising sales potential.
• Make more informed business decisions from insightful and in-depth analysis of
Mavrilimumab performance.
• Obtain sales forecast for Mavrilimumab from 2013-2023 in top 6 countries (the US, France,
Germany, Italy, Spain and the UK).
Inquire for discount on this Report @
http://www.rnrmarketresearch.com/contacts/discount?rname=312807 .
Mavrilimumab Market Analysis and Forecast to 2023
© RnRMarketResearch.com ; sales@rnrmarketresearch.com ;
+1 888 391 5441
Table of Contents
• 1 Table of Contents 5
• 2 Introduction 10
• 3 Disease Overview 15
• 4 Disease Management 22
• 5 Competitive Assessment 40
• 6 Unmet Need and Opportunity 42
• 7 Pipeline Assessment 54
• 8 Mavrilimumab 62
• 9 Appendix 68
• List of Tables
• List of Figures
Inquire for sample of this report @ http://www.rnrmarketresearch.com/contacts/request-
sample?rname=312807 .
Mavrilimumab Market Analysis and Forecast to 2023
© RnRMarketResearch.com ; sales@rnrmarketresearch.com ;
+1 888 391 5441
Related Market Reports:
PharmaPoint: Rheumatoid Arthritis – Japan Drug Forecast and Market Analysis to 2023
research report is now available with RnRMarketResearch.com @
http://www.rnrmarketresearch.com/pharmapoint-rheumatoid-arthritis-japan-drug-forecast-
and-market-analysis-to-2023-market-report.html
Rituxan/Mabthera (rituximab) (Rheumatoid Arthritis) – Forecast and Market Analysis to
2023 research report is now available with RnRMarketResearch.com @
http://www.rnrmarketresearch.com/rituxanmabthera-rituximab-rheumatoid-arthritis-
forecast-and-market-analysis-to-2023-market-report.html
Mavrilimumab Market Analysis and Forecast to 2023
For more details contact Mr. Ritesh Tiwari: sales@rnrmarketresearch.com /
+18883915441
© RnRMarketResearch.com ; sales@rnrmarketresearch.com ;
+1 888 391 5441
RnR Market Research
RnRMarketResearch.com, an online repository of market research reports, offers in-depth
analysis of over 5000 market segments. RnR Market Research library has syndicated reports
by leading market research publishers across the globe.
Mavrilimumab Market Analysis and Forecast to 2023

Contenu connexe

Dernier

HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptxHELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptxHelene Heckrotte
 
Data skills for Agile Teams- Killing story points
Data skills for Agile Teams- Killing story pointsData skills for Agile Teams- Killing story points
Data skills for Agile Teams- Killing story pointsyasinnathani
 
Talent Management research intelligence_13 paradigm shifts_20 March 2024.pdf
Talent Management research intelligence_13 paradigm shifts_20 March 2024.pdfTalent Management research intelligence_13 paradigm shifts_20 March 2024.pdf
Talent Management research intelligence_13 paradigm shifts_20 March 2024.pdfCharles Cotter, PhD
 
Plano de marketing- inglês em formato ppt
Plano de marketing- inglês  em formato pptPlano de marketing- inglês  em formato ppt
Plano de marketing- inglês em formato pptElizangelaSoaresdaCo
 
MC Heights construction company in Jhang
MC Heights construction company in JhangMC Heights construction company in Jhang
MC Heights construction company in Jhangmcgroupjeya
 
Introduction to The overview of GAAP LO 1-5.pptx
Introduction to The overview of GAAP LO 1-5.pptxIntroduction to The overview of GAAP LO 1-5.pptx
Introduction to The overview of GAAP LO 1-5.pptxJemalSeid25
 
Mihir Menda - Member of Supervisory Board at RMZ
Mihir Menda - Member of Supervisory Board at RMZMihir Menda - Member of Supervisory Board at RMZ
Mihir Menda - Member of Supervisory Board at RMZKanakChauhan5
 
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John Meulemans
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John MeulemansBCE24 | Virtual Brand Ambassadors: Making Brands Personal - John Meulemans
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John MeulemansBBPMedia1
 
Project Brief & Information Architecture Report
Project Brief & Information Architecture ReportProject Brief & Information Architecture Report
Project Brief & Information Architecture Reportamberjiles31
 
7movierulz.uk
7movierulz.uk7movierulz.uk
7movierulz.ukaroemirsr
 
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdfAMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdfJohnCarloValencia4
 
Ethical stalking by Mark Williams. UpliftLive 2024
Ethical stalking by Mark Williams. UpliftLive 2024Ethical stalking by Mark Williams. UpliftLive 2024
Ethical stalking by Mark Williams. UpliftLive 2024Winbusinessin
 
Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access
 
Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access
 
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISINGUNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISINGlokeshwarmaha
 
Entrepreneurship & organisations: influences and organizations
Entrepreneurship & organisations: influences and organizationsEntrepreneurship & organisations: influences and organizations
Entrepreneurship & organisations: influences and organizationsP&CO
 
PDT 89 - $1.4M - Seed - Plantee Innovations.pdf
PDT 89 - $1.4M - Seed - Plantee Innovations.pdfPDT 89 - $1.4M - Seed - Plantee Innovations.pdf
PDT 89 - $1.4M - Seed - Plantee Innovations.pdfHajeJanKamps
 
NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023Steve Rader
 
A flour, rice and Suji company in Jhang.
A flour, rice and Suji company in Jhang.A flour, rice and Suji company in Jhang.
A flour, rice and Suji company in Jhang.mcshagufta46
 

Dernier (20)

HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptxHELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
 
WAM Corporate Presentation Mar 25 2024.pdf
WAM Corporate Presentation Mar 25 2024.pdfWAM Corporate Presentation Mar 25 2024.pdf
WAM Corporate Presentation Mar 25 2024.pdf
 
Data skills for Agile Teams- Killing story points
Data skills for Agile Teams- Killing story pointsData skills for Agile Teams- Killing story points
Data skills for Agile Teams- Killing story points
 
Talent Management research intelligence_13 paradigm shifts_20 March 2024.pdf
Talent Management research intelligence_13 paradigm shifts_20 March 2024.pdfTalent Management research intelligence_13 paradigm shifts_20 March 2024.pdf
Talent Management research intelligence_13 paradigm shifts_20 March 2024.pdf
 
Plano de marketing- inglês em formato ppt
Plano de marketing- inglês  em formato pptPlano de marketing- inglês  em formato ppt
Plano de marketing- inglês em formato ppt
 
MC Heights construction company in Jhang
MC Heights construction company in JhangMC Heights construction company in Jhang
MC Heights construction company in Jhang
 
Introduction to The overview of GAAP LO 1-5.pptx
Introduction to The overview of GAAP LO 1-5.pptxIntroduction to The overview of GAAP LO 1-5.pptx
Introduction to The overview of GAAP LO 1-5.pptx
 
Mihir Menda - Member of Supervisory Board at RMZ
Mihir Menda - Member of Supervisory Board at RMZMihir Menda - Member of Supervisory Board at RMZ
Mihir Menda - Member of Supervisory Board at RMZ
 
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John Meulemans
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John MeulemansBCE24 | Virtual Brand Ambassadors: Making Brands Personal - John Meulemans
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John Meulemans
 
Project Brief & Information Architecture Report
Project Brief & Information Architecture ReportProject Brief & Information Architecture Report
Project Brief & Information Architecture Report
 
7movierulz.uk
7movierulz.uk7movierulz.uk
7movierulz.uk
 
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdfAMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
 
Ethical stalking by Mark Williams. UpliftLive 2024
Ethical stalking by Mark Williams. UpliftLive 2024Ethical stalking by Mark Williams. UpliftLive 2024
Ethical stalking by Mark Williams. UpliftLive 2024
 
Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024
 
Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024
 
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISINGUNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
 
Entrepreneurship & organisations: influences and organizations
Entrepreneurship & organisations: influences and organizationsEntrepreneurship & organisations: influences and organizations
Entrepreneurship & organisations: influences and organizations
 
PDT 89 - $1.4M - Seed - Plantee Innovations.pdf
PDT 89 - $1.4M - Seed - Plantee Innovations.pdfPDT 89 - $1.4M - Seed - Plantee Innovations.pdf
PDT 89 - $1.4M - Seed - Plantee Innovations.pdf
 
NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023
 
A flour, rice and Suji company in Jhang.
A flour, rice and Suji company in Jhang.A flour, rice and Suji company in Jhang.
A flour, rice and Suji company in Jhang.
 

Top 6 countries Discussed in Mavrilimumab Market Research Report

  • 1. Mavrilimumab Market Analysis and Forecast to 2023 By GlobalData Browse More Reports On Life Sciences @ http://www.rnrmarketresearch.com/reports/life-sciences . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441 Single User License: US $3495 Published: Dec 2014
  • 2. Mavrilimumab Market Analysis and Forecast to 2023 Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch. Complete report available @ http://www.rnrmarketresearch.com/mavrilimumab- rheumatoid-arthritis-forecast-and-market-analysis-to-2023-market-report.html . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441
  • 3. © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441 Mavrilimumab, also known as CAM3001, is in Phase IIb of development for RA by MedImmune, a subsidiary of AstraZeneca. It is a human mAb targeted against the alpha subunit of the GM-CSF receptor. GM-CSF levels are elevated in the serum, synovial fluid, and synoviocytes of patients with RA. Inhibition of GM-CSF activity is proposed to reduce the activation, differentiation, and recruitment of macrophages and neutrophils in the damaged and inflamed joints of RA patients. Scope • Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. • Detailed information on Mavrilimumab including product description, safety and efficacy profiles as well as a SWOT analysis. • Sales forecast for Mavrilimumab for the top 6 countries from 2013 to 2023. • Sales information covered for the US, France, Germany, Italy, Spain and the UK. Purchase a Copy of this Report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=312807 . Mavrilimumab Market Analysis and Forecast to 2023
  • 4. © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441 Reasons to buy • Understand and capitalize by identifying products that are most likely to ensure a robust return. • Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis. • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential. • Make more informed business decisions from insightful and in-depth analysis of Mavrilimumab performance. • Obtain sales forecast for Mavrilimumab from 2013-2023 in top 6 countries (the US, France, Germany, Italy, Spain and the UK). Inquire for discount on this Report @ http://www.rnrmarketresearch.com/contacts/discount?rname=312807 . Mavrilimumab Market Analysis and Forecast to 2023
  • 5. © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441 Table of Contents • 1 Table of Contents 5 • 2 Introduction 10 • 3 Disease Overview 15 • 4 Disease Management 22 • 5 Competitive Assessment 40 • 6 Unmet Need and Opportunity 42 • 7 Pipeline Assessment 54 • 8 Mavrilimumab 62 • 9 Appendix 68 • List of Tables • List of Figures Inquire for sample of this report @ http://www.rnrmarketresearch.com/contacts/request- sample?rname=312807 . Mavrilimumab Market Analysis and Forecast to 2023
  • 6. © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441 Related Market Reports: PharmaPoint: Rheumatoid Arthritis – Japan Drug Forecast and Market Analysis to 2023 research report is now available with RnRMarketResearch.com @ http://www.rnrmarketresearch.com/pharmapoint-rheumatoid-arthritis-japan-drug-forecast- and-market-analysis-to-2023-market-report.html Rituxan/Mabthera (rituximab) (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023 research report is now available with RnRMarketResearch.com @ http://www.rnrmarketresearch.com/rituxanmabthera-rituximab-rheumatoid-arthritis- forecast-and-market-analysis-to-2023-market-report.html Mavrilimumab Market Analysis and Forecast to 2023
  • 7. For more details contact Mr. Ritesh Tiwari: sales@rnrmarketresearch.com / +18883915441 © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441 RnR Market Research RnRMarketResearch.com, an online repository of market research reports, offers in-depth analysis of over 5000 market segments. RnR Market Research library has syndicated reports by leading market research publishers across the globe. Mavrilimumab Market Analysis and Forecast to 2023